Close Menu

Regulus

Regulus Therapeutics this week announced that it has received a milestone payment from Biogen Idec as part of the companies' ongoing partnership to identify microRNA biomarkers for multiple sclerosis.

Regulus Therapeutics this week released new preclinical data showing that microRNA-21 is implicated in the fibrotic kidney condition Alport syndrome and indicated that the program could likely yield its next clinical candidate.

Arrowhead Research and Regulus Therapeutics this week announced the presentation of preclinical data on their hepatitis drug candidates.

Regulus Therapeutics this week announced that AstraZeneca has selected an undisclosed oncology target under the companies' ongoing partnership to develop microRNA-targeting drugs for oncology and cardiovascular and metabolic diseases.

Arcturus Therapeutics has named Zachary Zimmerman as its chief business officer.

Title: Compositions and Methods for Inhibiting Expression of a Target Gene
Patent Number: 8,546,143
Filed: Sept. 29, 2010
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013

Regulus Therapeutics this week said that it has completed its previously announced public stock offering of roughly 5.1 million shares at $9.50 a share.

Regulus Therapeutics said this week that it has priced the public offering of 4.5 million shares of its common stock at $9.50 each.
As of midday Wednesday, Regulus’ stock was trading around $10.05 a share.

MiRagen Therapeutics has named Aimee Jackson as its director of target development and Christopher Morl as its chief business officer.

Pages

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.